abstract |
The present invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of formula I, and pharmaceutically acceptable salts thereof, wherein B 1 to B 3 and R 1 to R 7 are as described in the specification and claims defined in the book. These compounds are GPBAR1 agonists and can therefore be used as drugs for the treatment of diseases such as type II diabetes. |